{
    "organizations": [],
    "uuid": "5592c50a79f0e279ec54c5421546c9859480e321",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/27/globe-newswire-editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2017-corporate-update-and-results.html",
    "ord_in_thread": 0,
    "title": "Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2017.\nTo access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 2449529. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.\nAbout Editas Medicine\nAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com .\nContacts\nMedia:\nCristi Barnett\n(617) 401-0113\ncristi.barnett@editasmed.com\nInvestors:\nMark Mullikin\n(617) 401-9083\nmark.mullikin@editasmed.com\nSource:Editas Medicine, Inc.",
    "published": "2018-02-28T00:01:00.000+02:00",
    "crawled": "2018-02-28T01:43:00.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "globe",
        "newswire",
        "editas",
        "medicine",
        "nasdaq",
        "edit",
        "leading",
        "genome",
        "editing",
        "company",
        "today",
        "announced",
        "webcast",
        "tuesday",
        "march",
        "6th",
        "et",
        "discus",
        "corporate",
        "update",
        "result",
        "fourth",
        "quarter",
        "full",
        "year",
        "access",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "provide",
        "passcode",
        "live",
        "webcast",
        "presentation",
        "available",
        "investor",
        "medium",
        "section",
        "editas",
        "website",
        "editas",
        "medicine",
        "leading",
        "genome",
        "editing",
        "company",
        "editas",
        "medicine",
        "focused",
        "translating",
        "power",
        "potential",
        "genome",
        "editing",
        "system",
        "robust",
        "pipeline",
        "treatment",
        "people",
        "living",
        "serious",
        "disease",
        "around",
        "world",
        "editas",
        "medicine",
        "aim",
        "discover",
        "develop",
        "manufacture",
        "commercialize",
        "transformative",
        "durable",
        "precision",
        "genomic",
        "medicine",
        "broad",
        "class",
        "disease",
        "latest",
        "information",
        "scientific",
        "presentation",
        "please",
        "visit",
        "contact",
        "medium",
        "cristi",
        "barnett",
        "investor",
        "mark",
        "mullikin",
        "source",
        "editas",
        "medicine",
        "inc"
    ]
}